Patents Issued in June 19, 2018
  • Compositions and methods for stimulation MAGP-1 to improve the appearance of skin
    Patent number: 9999587
    Abstract: The present disclosure relates to methods for treating, preventing and improving the condition and aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, by application of one or a combination of natural compounds or extracts that stimulate MAGP-1 expression and which improves the appearance of aged and/or photodamaged skin. The compositions of the invention are topically applied to the skin, or are delivered by directed means to a site in need thereof in an amount effective to improve the condition and aesthetic appearance of skin.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: June 19, 2018
    Assignee: Avon Products, Inc.
    Inventors: Qian Zheng, Siming W. Chen, Uma Santhanam, John W. Lyga
  • Topical skin care formulations and methods of using same
    Patent number: 9999588
    Abstract: A natural and dual-functioning topical skin care composition for exfoliating and moisturizing the skin. The compositions include undissolved, water-soluble Camu Camu particles as an exfoliant in a pharmaceutically acceptable carrier. The compositions are anhydrous or substantially free of water to retain the exfoliant Camu Camu particles in the composition as it is applied and rubbed onto the skin. The compositions provide a rinse-free way to exfoliate the skin with the application of minute amounts of water to dissolve the vitamin C enriched Camu Camu particles of the compositions that may then be absorbed into the skin.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: June 19, 2018
    Inventors: Lisa Stewart, Ara Asadorian
  • Culture medium of adipose-derived stem cell, method for preparing the same, and composition including the same for promoting hair growth
    Patent number: 9999589
    Abstract: Provided are a culture medium of an adipose-derived stem cell, a method for preparing the same, and a composition for promoting hair growth, in which the composition includes the culture medium. The adipose-derived stem cell (ADSC-T) according to the present invention exhibits long lifespan, improved cell proliferation rate, and extended proliferation period, as compared with a primary adipose-derived stem cell (ADSC), and thus, the adipose-derived stem cell (ADSC-T) can be usefully used for the study about the adipose-derived stem cell and the mass production of the culture medium of the adipose-derived stem cell. In addition, according to the present invention, the culture medium of the adipose-derived stem cell (ADSC-T) that expresses a T antigen of SV40 exhibits excellent hair growth effectiveness and can be usefully used as a raw material for the hair loss prevention and hair growing agents.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: June 19, 2018
    Assignee: CHANGWON NATIONAL UNIVERSITY INDUSTRY ACADEMY COOP
    Inventors: Dong Wan Kim, Mi Jung Seo, Gwang Lee, Woo Hong Joo, Sun Hee Kim
  • Diclofenac formulations
    Patent number: 9999590
    Abstract: The subject invention provides improved diclofenac gel formulations.
    Type: Grant
    Filed: July 4, 2013
    Date of Patent: June 19, 2018
    Assignee: Ferring B.V.
    Inventors: Arnaud Grenier, Dario N. Carrara
  • Immunogenic composition against
    Patent number: 9999591
    Abstract: The inventive subject matter relates to an immunogenic composition against Campylobacter jejuni comprising isolated capsule polysaccharide from selected pathogenic Campylobacter jejuni strains. The inventive subject matter also relates to methods of using the polysaccharide compositions in inducing and anti-C. jejuni immune response.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: June 19, 2018
    Assignee: The United States of America as Represented by the Secretary of the Navy
    Inventors: Patricia Guerry, Mario Artur Monteiro
  • Intrauterine delivery system for contraception
    Patent number: 9999592
    Abstract: The invention relates to a method for contraception and for reducing menstrual problems and inducing amenorrhea, wherein an intrauterine delivery device is used for the controlled release of a combination of progestogen or a drug having a progestogenic activity and at least one therapeutically active substance capable of preventing or suppressing abnormal and/or irregular endometrial bleeding over a prolonged period of time.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: June 19, 2018
    Assignee: Bayer Oy
    Inventors: Bernd Duesterberg, Manja Ahola, Jyrki Pihlaja, Heikki Lyytikäinen, Harri Jukarainen, Satu Kleemola, Tero Parkatti, Tuula Valo, Ina Gröticke, Bernhard Lindenthal, Ulrike Fuhrmann
  • Method and composition for treating ocular hypertension and glaucoma
    Patent number: 9999593
    Abstract: The present invention relates to an ophthalmic aqueous composition containing PGF2? analogs for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2? analogs in an aqueous composition.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: June 19, 2018
    Assignees: SANTEN PHARMACEUTICAL CO., LTD., ASAHI GLASS CO., LTD.
    Inventors: Timo Reunamaki, Pertti Pellinen, Olli Oksala, Kari Lehmussaari
  • Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage
    Patent number: 9999594
    Abstract: The objective of the present invention is to provide a new medicinal use of clarithromycin. The present invention is a therapeutic agent or a preventive agent for meibomian gland dysfunction or meibomian gland blockage and comprises clarithromycin as an active ingredient. The dosage form is preferably an eye drop or eye ointment.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: June 19, 2018
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kazutaka Kido, Takashi Nagano
  • Eye device
    Patent number: 9999595
    Abstract: The invention provides a sustained release intraocular drug delivery device comprising: (a) a polymeric matrix core into which at least one therapeutic agent is mixed, and; (b) a polymeric coating completely surrounding said polymeric matrix material; wherein said polymeric matrix core and polymeric coating are insoluble and inert in ocular fluids, and wherein said sustained release intraocular drug delivery device has a compliant annular segment shape and is to be inserted into the sulcus of the intact and/or pseudophakic eye.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: June 19, 2018
    Assignee: EYED PHARMA
    Inventors: Jean-Marie Rakic, Jean-Michel Foidart
  • Controlled release hydrogels
    Patent number: 9999596
    Abstract: Formulations and methods for their preparation including a hydrogel including a crosslinked matrix comprising a polymer, and a one or more liposomes containing a therapeutic agent.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: June 19, 2018
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Patrick J. Sinko, Stanley Stein, Anita Lalloo
  • Formation of particle structures
    Patent number: 9999597
    Abstract: Irregular, angular particles are produced by a manufacturing method that comprises forming a film on a substrate and then stretching the substrate along one or more axes to fracture the film into particle structures. The substrate may be moved continuously along a production line as the film is formed and may be stretched by accelerating that movement. The substrate may comprise a surface with elevated patterns to control the fracturing of the film. The particles are particularly suitable for the transdermal delivery of a biologically active substance into the body of a patient.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: June 19, 2018
    Assignee: NDM Technologies Limited
    Inventor: Dewan Fazlul Hoque Chowdhury
  • Pharmaceutical composition for gastric cancer treatment and/or prevention
    Patent number: 9999598
    Abstract: A method for treatment and/or prevention of gastric cancer is provided, and the method includes: administering a composition to a subject in need thereof, the composition comprising a carbonaceous material and an active particle positioned on the carbonaceous material and made of silver, gold, zinc, copper, aluminum, palladium, platinum, nickel, cobalt, calcium, titanium, chromium, silicon, or any combination thereof.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: June 19, 2018
    Assignee: FENG-CHIA UNIVERSITY
    Inventors: Tse-Hao Ko, Ming-Chien Hung
  • Polymer-polymer composite nanoassemblies and applications thereof
    Patent number: 9999599
    Abstract: The invention provides novel nanoscale delivery vehicles and composite nanoassemblies built from distinct nanoassembly units (e.g., block copolymer micelles and nanogels) with stoichiometric control. These intelligent composite nanoassemblies independently retain the key features of the nanoassembly units and greatly expand the potential functional features attainable based on the surface functionalization. The invention provides a novel approach to constructing nano-vehicles with controllable morphology based on combination of cooperative releasing mechanisms (e.g., redox sensitive nanogels and pH sensitive micelles). Two kinds of guests can be seperately and stably encapsulated in the composite nanocontainers, and then released sequentially under the stimulation of pH change and reduced glutathione.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: June 19, 2018
    Assignee: University of Massachusetts
    Inventors: Sankaran Thayumanavan, Conghui Yuan
  • Nanoparticle compositions
    Patent number: 9999600
    Abstract: The present invention provides, among other things, nanoparticle compositions including a plurality of nanoparticles, each of which is comprised of a biodegradable or biocompatible polymer arranged in a nanoparticle structure defining an internal lumen and an external surface and one or more of a preparation of hydrophilic cellular components and a preparation of hydrophobic cellular components. In some embodiments, the preparation of hydrophilic cellular components is encapsulated within the internal lumen and the preparation of hydrophobic cellular components is associated with the external surface. Various methods of making and using disclosed nanoparticle compositions are also provided.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: June 19, 2018
    Assignee: N-Fold LLC
    Inventors: Howard B. Sosin, Michael J. Caplan
  • Composition and method for inhibition of nerve transmission
    Patent number: 9999601
    Abstract: The presently claimed and disclosed invention(s) provides a therapeutically effective composition and method of inhibiting nerve cell transmission. In a preferred embodiment of the presently claimed and disclosed invention(s), the treatment of neuropathic pain utilizing terpene compounds isolated from plant essential oils or manufactured synthetically is detailed. These compounds, such as geraniol and citronellol, as well as chemical analogs thereof, used in combination or individually, can be used alone or in a composition with a pharmaceutically acceptable carrier in a suitable dosage form.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: June 19, 2018
    Assignee: NEUROQUEST INC.
    Inventors: Alexander McLellan, Frank Greenway
  • Liquid menthol compositions
    Patent number: 9999602
    Abstract: A composition is provided comprising: (i) menthol, and (ii) a carrier comprising a digestible edible oil, wherein said digestible edible oil is one that provides a composition which is a liquid at 20° C. after rising to that temperature from a lower temperature at which the oil was previously semisolid. The preferred edible oil is a medium-chain triglyceride oil, wherein the level of menthol in the composition is between 1-50% by total weight, so as to provide an menthol application rate of between 5 and 20 mg of menthol, and most preferably, about 10 mg menthol, in a single droplet of the composition. The composition can also include additional added vitamins and essential oils. A liquid method for administering menthol is provided.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: June 19, 2018
    Assignee: DDROPS COMPANY
    Inventors: Simon George Vieth, Chris James Temovsky, Reinhold William Vieth
  • Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer
    Patent number: 9999603
    Abstract: The present invention relates to compositions and methods for treatment of proliferative disease. In specific aspects, the present invention relates to compositions including (1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1-,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenemethanamine (leelamine) and arachidonyl trifluoromethyl ketone (ATK) in combination; methods for treatment of cancer including administration of leelamine and ATK in a subject in need thereof; and particularly methods for treatment of skin cancer including administration of leelamine and ATK in a subject in need thereof.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 19, 2018
    Assignee: The Penn State Research Foundation
    Inventors: Gavin P. Robertson, Omer F. Kuzu
  • Compounded solutions of diclofenac and lidocaine and methods
    Patent number: 9999604
    Abstract: A compounded topical solution may include approximately 85% to approximately 95% (v/v) diclofenac sodium topical solution, 1.5% (w/w), and approximately 5% to approximately 15% (v/v) lidocaine hydrochloride topical solution, 4% USP.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: June 19, 2018
    Assignee: CMPD LICENSING, LLC
    Inventor: Jay Richard Ray, II
  • Preparation for treatment of a non-oral treatment site comprising an active chlorine compound and amino acids
    Patent number: 9999605
    Abstract: A kit of parts for use in prevention and/or treatment of a non-oral treatment site, such as, sores, wounds, ulcers or the like, or a fistula or otitis. The kit of parts comprises a first aqueous component comprising one or more amino acids, and a second aqueous component comprising an active halogen compound, wherein the pH of the first component and/or the second component is about 9 to 11.5. There is also provided a treatment preparation prepared from the components and uses thereof in the prevention and/or treatment of a non-oral treatment site, such as, sores, wounds, ulcers or the like, or a fistula or otitis.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: June 19, 2018
    Assignee: RLS Global AB
    Inventors: Ulrica Almhöjd, Karin Bergqvist
  • Oral pharmaceutical composition of isotretinoin
    Patent number: 9999606
    Abstract: An oral pharmaceutical composition of isotretinoin and a carrier substrate, having isotretinoin in the form of gel, dispersion, solution or emulsion, which is absorbed onto the carrier substrate to form solid particles, powder, or granules. The oral pharmaceutical composition has enhanced bioavailability. A process is used for preparing the oral composition.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: June 19, 2018
    Assignee: Sun Pharmaceutical Industries Limited.
    Inventors: Rajesh Rao, Anuj Kumar Fanda, Satish Kumar Jain, Romi Barat Singh
  • Lipid comprising polyunsaturated fatty acids
    Patent number: 9999607
    Abstract: The present invention relates to extracted plant lipid, comprising fatty acids in an esterified form.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: June 19, 2018
    Assignees: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, GRAINS RESEARCH AND DEVELOPMENT CORPORATION, NUSEED PTY LTD
    Inventors: James Robertson Petrie, Surinder Pal Singh, Robert Charles de Feyter
  • Methods of therapeutic monitoring of nitrogen scavenging drugs
    Patent number: 9999608
    Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: June 19, 2018
    Assignee: Horizon Therapeutics, LLC
    Inventors: Bruce Scharschmidt, Masoud Mokhtarani
  • Methods for treating or preventing fatigue
    Patent number: 9999609
    Abstract: The present invention relates to the use of compounds of the invention for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: June 19, 2018
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Moise A. Khayrallah, Gary Bream, Stephen E. Butts, Susan Marie Melnick, Duncan Taylor
  • Pharmaceutical use of 3-benzylsulfonylpropionitrile
    Patent number: 9999610
    Abstract: The present invention is directed to a method of treating an inflammatory skin disease or disorder, such as dermatitis, psoriasis, acne, or rosacea. The method comprises administering to the subject 3-benzylsulfonylpropionitrile, in an amount effective to reduce or eliminate the symptoms of the inflammatory skin disease or disorder. Topical administration and oral administration are preferred route of administration.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: June 19, 2018
    Assignee: Olatec Therapeutics LLC
    Inventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Bresse, Scott A. Goodrich
  • SIRT 1 activator including syringaresinol
    Patent number: 9999611
    Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: June 19, 2018
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Byung Gyu Kim, Hyun Woo Jeong, Su Kyung Kim, Si Young Cho, Chan Woong Park, Dae Bang Seo, Wan Gi Kim, Sang Jun Lee
  • PPARs agonist activity enhancing drug
    Patent number: 9999612
    Abstract: A lifestyle disease improving drug is disclosed that enhances PPAR?, ? and ? agonist activities that includes a compound having the lactone structure in accordance with the chemical formula 6-alkyl-5,6-dihydro-2H-pyran-2-one, the alkyl containing 4, 5, or 6 carbons. Methods for enhancing PPAR?, ? and ? agonist activities in vertebrates or medically treating a vertebrate are disclosed. The methods include providing a composition of an active ingredient, the lifestyle disease improving drug, in a biologically acceptable medium and administering an effective amount of the composition to a vertebrate.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: June 19, 2018
    Assignee: TSUJIMOTO CHEMICAL CO., LTD.
    Inventor: Munekazu Iinuma
  • 2H-chromene derivatives as analgesic agents
    Patent number: 9999613
    Abstract: The invention relates to the use of the compound of general formula 1 or its spatial isomers as an analgesic drug. The compounds have high activity, low toxicity, may be used in medicine.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: June 19, 2018
    Assignee: OBSHESTVO S OGRANICHENNOI OTVETSVENNOSTJU “LEOFORS”
    Inventors: Ekaterina Vladimirovna Khaid, Alla Viktorovna Pavlova, Oksana Stanislavovna Mikhal'Chenko, Dina Vladimirovna Korchagina, Tatiana Genrihovna Tolstikova, Konstantin Petrovich Volcho, Veniamin Abramovich Khazanov, Nariman Faridovich Salakhutdinov
  • Combination for the prophylaxis and treatment of behavioural, mental, and cognitive disorders
    Patent number: 9999614
    Abstract: The invention relates to the field of pharmacology and practical medicine, namely, to the combined use of pharmaceutical compositions exhibiting a neurotropic action, alleviating manifestations of mental, behavioral, cognitive disorders in cases of organic damage of various origin to the central nervous system. The combination comprises Memantine and Melatonin in therapeutically efficient quantities. The combination enables to raise disease treatment effectiveness. 1 independent claim, 2 dependent claims. 2 examples, 7 tables.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: June 19, 2018
    Assignee: LTD “VALENTA-INTELLEKT”
    Inventors: Margarita Alekseevna Morozova, Allan Gerovich Beniashvili, Maxim Eduardovich Zapolskii
  • Autotaxin inhibitor compounds
    Patent number: 9999615
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: June 19, 2018
    Assignee: PHARMAKEA, INC.
    Inventors: John Howard Hutchinson, David Lonergan
  • Substituted bicyclic compounds as bromodomain inhibitors
    Patent number: 9999616
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: June 19, 2018
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, John Frederick Quinn, Bryan Cordell Duffy, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, He Zhao, Michael Ellis, Gregory Steven Wagner, Peter Ronald Young
  • Compositions for treating bacterial infections
    Patent number: 9999617
    Abstract: The present invention is antibiotic compositions having the ability to disrupt a MazEF complex in S. aureus. The compositions also have the ability to inhibit growth of S. aureus and as such are useful as antibiotic compounds.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: June 19, 2018
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Ambrose Cheung, Zhibiao Fu
  • Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
    Patent number: 9999618
    Abstract: The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: June 19, 2018
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, David J. Lockhart
  • Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
    Patent number: 9999619
    Abstract: The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 19, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Taisheng Huang, Chu-Biao Xue
  • CaMKK-? as a target for treating cancer
    Patent number: 9999620
    Abstract: Provided herein are compounds, compositions, including pharmaceutical compositions, having anti-cancer activity. Also provided are methods for diagnosing, detecting, and treating cancer in a subject, as well as a method for evaluating cancer stage in a subject, wherein the methods include determining the amount of a Ca2+/calmodulin dependent kinase kinase (CaMKK) in a sample. Further provided are methods of screening and identifying a compound that inhibits CaMKK.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: June 19, 2018
    Assignee: Duke University
    Inventors: Donald P. McDonnell, Daniel Frigo, Anthony R. Means
  • Medical use of artemisinin compounds and gephyrin agonists
    Patent number: 9999621
    Abstract: The invention refers to BTBD9 binders and gephyrin binders for medical use and in particular an artemisinin compound of general formula I for use in the treatment of a diabetes patient, as well as a method of identifying suitable lead candidates.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: June 19, 2018
    Assignee: CeMM—Forschungszentrum für Molekulare Medizin GmbH
    Inventors: Jin Li, Stefan Kubicek
  • Pyrazolothiazole compound and medicine comprising same
    Patent number: 9999622
    Abstract: The invention provides a pyrazolothiazole compound of the formula [I], or a pharmaceutically acceptable salt thereof: The compound of the invention has JAK1 inhibitory activity, and thus, immunosuppressive effect, anti-inflammatory effect and anti-proliferative effect, and is useful in the treatment of the diseases, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis and vasculitis, bronchial asthma, chronic obstructive pulmonary disease and eosinophilic sinusitis, nasal polyp.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: June 19, 2018
    Assignee: NIPPON SHINYAKU CO., LTD.
    Inventors: Yoshinobu Shiba, Satoshi Akiyama
  • Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
    Patent number: 9999623
    Abstract: Described herein arc methods of treating non-Hodgkin's lymphoma (NHL), wherein the non-Hodgkin's lymphoma (NHL) is selected from the group consisting of 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL); follicular lymphoma (FL); chronic lymphocytic leukemia (CLL); marginal zone lymphoma (MZL); diffuse large B-cell lymphoma (DLBCL); mantle cell lymphoma (MCL); transformed lymphoma (TL); and peripheral T-cell lymphoma (PTCL). comprising administering to a patient in need thereof a 2,3-dihydroimidazo[1,2-c] quinazolinc compound, or a salt thereof.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: June 19, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ningshu Liu, Katja Haike, Juliane Paul, Antje Margret Wengner
  • Combination Alzheimer therapy using anti-N3pGlu Abeta antibodies + a BACE inhibitor
    Patent number: 9999624
    Abstract: The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof; in combination with an effective amount of an anti-N3pGlu Abeta monoclonal antibody.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: June 19, 2018
    Assignee: Eli Lilly and Company
    Inventors: Patrick Cornelious May, Dustin James Mergott
  • Pyrrolobenzodiazepine compounds
    Patent number: 9999625
    Abstract: The invention relates to pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) of formula (I) and in particular to PBD dimers linked through the C1 position, and PBD monomers linked through the C1 position to aromatic groups, and pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular as anti-proliferative agents.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: June 19, 2018
    Assignee: Femtogenix Limited
    Inventors: David Edwin Thurston, Khondaker Mirazur Rahman, Paul Joseph Mark Jackson
  • Mineral amino-acid complexes of active agents
    Patent number: 9999626
    Abstract: The present invention provides compounds of Formula I and related compositions and methods.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: June 19, 2018
    Assignee: Thetis Pharmaceuticals LLC
    Inventors: Frank C. Sciavolino, Gary Mathias
  • Methods of treating erectile dysfunction
    Patent number: 9999627
    Abstract: An active agent for use in a method of, or for use in the preparation of a medicament for, treating or inhibiting the development of erectile dysfunction and/or incontinence following pelvic radiation treatment in a subject in need thereof, comprising administering said subject an active agent in a treatment effective amount, is described. The active agent has the general structure of Formula I or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: June 19, 2018
    Assignees: BioMimetix, JV, LLC, National Jewish Health
    Inventors: James D. Crapo, Rebecca Oberley Deegan
  • Neridronic acid for treating complex regional pain syndrome
    Patent number: 9999628
    Abstract: Osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: June 19, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
    Patent number: 9999629
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: June 19, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Traditional chinese medicine composition, and preparation and application thereof
    Patent number: 9999630
    Abstract: A traditional Chinese medicine composition for treating cardiovascular disease, and a preparation thereof, particularly a micro drop pill preparation thereof, and a method for preparing the preparation; the method for preparing the micro drop pill preparation can be used to prepare drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: June 19, 2018
    Assignee: Tasly Pharmaceutical Group Co., Ltd.
    Inventors: Xijun Yan, Naifeng Wu, Kaijing Yan, Zhengliang Ye, Shunnan Zhang, Lihong Zhou, Wensheng Zhang, Hai'ou Dong
  • Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
    Patent number: 9999631
    Abstract: A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of joint pain. The composition includes pro-inflammatory low molecular weight microbial fermented sodium hyaluronate fragments having a molecular weight of 0.5 to 300 kilodaltons (kDa) in an oral dosage form.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: June 19, 2018
    Assignee: U.S. NUTRACEUTICALS, LLC
    Inventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moerck
  • Inhibition of pancreatic lipase
    Patent number: 9999632
    Abstract: The present invention provides the use of an alginate Io inhibit pancreatic lipase. The use may be directed to the control of weight in animals including human beings. Preferably the fraction of guluronate dimers in the alginate is at least 0.5.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: June 19, 2018
    Assignees: RD Biomed Limited, University of Newcastle upon Tyne
    Inventors: Johnathan Craig Richardson, Peter William Dettmar, Matthew David Wilcox, Iain Andrew Brownlee, Jeffrey Peter Pearson
  • Antimicrobial cationic polycarbonates
    Patent number: 9999633
    Abstract: Antimicrobial cationic polymers having one or two cationic polycarbonate chains were prepared by organocatalyzed ring opening polymerization. One antimicrobial cationic polymer has a polymer chain consisting essentially of cationic carbonate repeat units linked to one or two end groups. The end groups can comprise a covalently bound form of biologically active compound such as cholesterol. Other antimicrobial cationic polymers have a random copolycarbonate chain comprising a minor mole fraction of hydrophobic repeat units bearing a covalently bound form of a vitamin E and/or vitamin D2. The cationic polymers exhibit high activity and selectivity against Gram-negative and Gram-positive microbes and fungi.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: June 19, 2018
    Assignees: International Business Machines Corporation, Agency For Science, Technology And Research
    Inventors: Willy Chin, Daniel J. Coady, Amanda C. Engler, James L. Hedrick, Ashlynn L. Z. Lee, Victor W. L. Ng, Zhan-Yuin Ong, Yi Yan Yang
  • Dissolution stability of calcium carbonate tablets
    Patent number: 9999634
    Abstract: The present invention relates to a method for the preparation of a tablet comprising at least 50% w/w of calcium carbonate, the method comprising i) providing a particulate composition comprising a) calcium carbonate, b) a binding sugar alcohol selected from sorbitol or isomalt, or combinations thereof, c) a non-binding sugar alcohol selected from mannitol, maltitol or xylitol, or combinations thereof, and ii) compressing said composition using a tabletting machine equipped with at least one pair of punches and dies, wherein the pair of punches and die before filling the die with said particulate composition is sprayed with a composition comprising a lubricant selected from magnesium stearate, calcium stearate or stearic acid or combinations thereof.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: June 19, 2018
    Assignee: Takeda AS
    Inventors: Peder Mohr Olsen, Poul Egon Bertelsen, Thomas Thisted, Henrik Ravn Aage
  • Methods and compositions for treating inflammatory disorders
    Patent number: 9999635
    Abstract: The present invention provides methods for treating conditions that involve infection and/or inflammation, including acute and chronic inflammation, as well as delayed-type and immediate-type hypersensitivity. The invention in various embodiments provides methods for treating microbial infection and the associated inflammatory response, as well methods for treating inflammatory conditions that spawn or are susceptible to secondary microbial infection. Further, the invention provides methods for treating inflammation, such as chronic inflammation, without any associated microbial infection.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: June 19, 2018
    Assignee: REALM THERAPEUTICS, INC.
    Inventors: Claire Sampson, Mark Sampson, Svetlana Panicheva, Cary Schockemoehl
  • Insulin-mimetics as therapeutic adjuncts for bone regeneration
    Patent number: 9999636
    Abstract: Methods of promoting bone healing or regeneration by locally administering insulin mimetic agents to patients in need thereof and new uses of insulin-mimetic compounds for accelerating bone-healing processes are disclosed. Bone injury treatment and void filler devices, products and kit suitable for local administration of insulin-mimetic, agents or compositions thereof to patients in need of such treatment are also disclosed.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: June 19, 2018
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Sheldon S. Lin, David N. Paglia, James P. O'Connor, Joseph Benevenia, Aaron Wey, Sangeeta Subramanian, John Koerner, Paul Chirichella, Michael J. Vives